IRAK4 蛋白降解——治疗自身免疫系统疾病的潜在新型靶点
2021年5月22日 · 目前 IRAK4 靶点临床进度最靠前的是 辉瑞 开发的 IRAK4 激酶抑制剂 PF-06550833， 已经在针对 RA 的二期临床试验中看到了初步的效果（Patients with moderately to …
Investigational IRAK-4 inhibitors for the treatment of rheumatoid ...
Interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors are novel agents designed to suppress immune signaling pathways involved in inflammation and joint destruction in RA. …
IRAK4 inhibition: a promising strategy for treating RA joint ...
We showed that IRAK4 inhibitor (i) therapy attenuated RA disease activity by blocking TLR7-induced M1 MΦ or FLS activation, as well as monokine-modulated Th1/Th17 cell polarization. …
Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) …
2024年12月1日 · Interleukin-1 receptor-related kinase (IRAK4) is a widely expressed serine/threonine kinase involved in the regulation of innate immunity. IRAK4 plays a pivotal …
IRAK4 inhibitor attenuates inflammation - Nature
2021年9月28日 · A new study shows that the IRAK4 small-molecule inhibitor PF-06650833 reduces inflammation in rodent models of rheumatoid arthritis (RA) and lupus and basal …
聚焦药靶：抗癌更要抗炎，IRAK4的最新研究进展 - 健康界
2022年5月15日 · PF-06650833是由辉瑞开发的有效和选择性的IRAK4抑制剂，在针对活动性类风湿关节炎和甲氨蝶呤反应不足患者的疗效和安全性的II期临床试验中，研究显示在第 12 周， …
We showed that IRAK4 inhibitor (i) therapy attenuated RA disease activity by blocking TLR7-induced M1 M or. FLS activation, as well as monokine-modulated Th1/Th17 cell polarization. …
The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF
Objective: To investigate the role of PF-06650833, a highly potent and selective small-molecule inhibitor of interleukin-1-associated kinase 4 (IRAK4), in autoimmune pathophysiology in vitro, …
A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis …
2023年3月1日 · In this study, we performed virtual screening and identified a dual inhibitor of IRAK4/PIM1 kinase, KIC-0101. We confirmed that KIC-0101 reduced inflammation and …
IRAK4 inhibition: a promising strategy for treating RA joint ...
2020年5月15日 · We showed that IRAK4 inhibitor (i) therapy attenuated RA disease activity by blocking TLR7-induced M1 MΦ or FLS activation, as well as monokine-modulated Th1/Th17 …